The group's principal activities are to conduct research and develop products and processes intended to treat major medical conditions in which lipids, or fat components, play a key role. Its technologies are based on a patented process that selectively removes lipids from proteins. This unique delipidation process has the potential for far-reaching implications for human health. It may provide an effective therapeutic effect on many infectious agents, including the viruses that cause aids, hepatitis b and c, as well as reverse cardio and cerebrovascular disease.
